Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NEK2 | P51955 | 2/20 | 0.58 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880724 | 0.85 | KDM4E (0.44) | KDM4ECYP2C19NEK2MALT1KMT2A | |
| SCHEMBL2421306 | 0.84 | MALT1 (0.70) | KDM4ECYP2C19NEK2MALT1KMT2A | |
| SCHEMBL4876457 | 0.83 | MALT1 (0.60) | KDM4EMALT1KMT2ARECQL | |
| SCHEMBL24377504 | 0.83 | MALT1 (0.57) | KDM4EMALT1RECQL | |
| SCHEMBL4881098 | 0.83 | DYRK1A (0.48) | KDM4ECYP2C19MALT1KMT2AALDH1A1 | |
| SCHEMBL4524152 | 0.82 | NEK2 (0.67) | KDM4ECYP2C19NEK2MALT1KMT2A | |
| SCHEMBL238160 | 0.82 | KDM4E (0.60) | KDM4ECYP2C19NEK2MALT1KMT2A | |
| SCHEMBL1728915 | 0.82 | KMT2A (0.50) | KDM4ECYP2C19MALT1KMT2ARECQL | |
| SCHEMBL2008677 | 0.81 | MALT1 (0.46) | KDM4EMALT1KMT2ARECQLDYRK1A | |
| SCHEMBL3104049 | 0.80 | NEK2 (0.59) | KDM4ECYP2C19NEK2MALT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | QPCT, QPCTL, GLUL | KDM4E 2763/4885CYP2C19 3853/4885NEK2 4292/4885 |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | KDM4E 3654/4885CYP2C19 528/4885NEK2 1081/4885 |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | KDM4E 4115/4885CYP2C19 1390/4885NEK2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.